Stock TPST TEMPEST THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.54 USD +1.72% Intraday chart for Tempest Therapeutics, Inc. +14.19% -19.55%
Apr. 09 Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting CI
Apr. 04 Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
AQ
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
GL
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting
CI
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
GL
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
AQ
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
CI
Tempest Therapeutics : Corporate Presentation - April 2024
PU
Tempest Therapeutics : Corporate Presentation - March 2024
PU
Tempest Reports Year End 2023 Financial Results and Provides Business Update
AQ
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tempest Reports Year End 2023 Financial Results and Provides Business Update
GL
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K
PU
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
BU
Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13
MT
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
GL
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
AQ
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types
CI
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
GL
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TPST Stock
  4. News Tempest Therapeutics, Inc.